{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:12:42Z","timestamp":1793229162531,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The potential role of adjunctive anti-inflammatory therapy to enhance tuberculosis (TB) treatment has recently received increasing interest. There is, therefore, a need to broadly examine current host-directed therapies (HDTs) that could accelerate treatment response and improve TB outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis included randomised controlled trials of vitamin D and other HDT agents in patients receiving antibiotic treatment for pulmonary TB. Sputum smear conversion rate at 4\u20138\u2009weeks was the primary outcome. Secondary outcomes included blood indices associated with infectivity and inflammation, chest radiology and incidence of adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty-five studies were screened for eligibility after the initial search, which yielded more than 1000 records. Of the 2540 participants in the 15 trials included in the meta-analysis, 1898 (74.7%) were male, and the age at entry ranged from 18 to 70\u2009years. There was a 38% significantly (\n                      <jats:italic>RR<\/jats:italic>\n                      1.38, 95%\n                      <jats:italic>CI\u2009=<\/jats:italic>\n                      \u00a01.03\u20131.84) increased sputum smear negativity in patients administered with vitamin D in addition to standard TB treatment than those receiving only the TB treatment. Patients treated with other HDT anti-inflammatory agents in addition to TB treatment also had a 29% significantly increased sputum smear conversion rate (\n                      <jats:italic>RR<\/jats:italic>\n                      1.29, 95%\n                      <jats:italic>CI\u2009=<\/jats:italic>\n                      \u00a01.09\u20131.563). Lymphocyte to monocyte ratio was significantly higher in the vitamin D treatment groups compared to the controls (3.52 vs 2.70, 95%\n                      <jats:italic>CI<\/jats:italic>\n                      for difference 0.16\u20131.11,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.009) and (adjusted mean difference 0.4, 95% CI 0.2 -- 0.6;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.001); whilst tumour necrosis factor-alpha (TNF-\u03b1) showed a trend towards a reduction in prednisolone (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u20090.001) and pentoxifylline (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.27) treatment groups. Vitamin D and N-acetylcysteine also accelerated radiographic resolution in treatment compared to placebo at 8\u2009weeks. No differences were observed in the occurrence of adverse events among all HDT treatments.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Vitamin D and other anti-inflammatory HDT medications used as adjunct TB treatment may be well tolerated and effective. They significantly improved sputum smear conversion rate and chest radiological appearance, and also exhibited an inflammation resolution effect.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12931-020-01488-9","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:12:03Z","timestamp":1598400723000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The effects of anti-inflammatory agents as host-directed adjunct treatment of tuberculosis in humans: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5950-2935","authenticated-orcid":false,"given":"Frank Ekow Atta","family":"Hayford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin Claire","family":"Dolman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Blaauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arista","family":"Nienaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius Mattheus","family":"Smuts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Malan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,26]]},"reference":[{"key":"1488_CR1","unstructured":"WHO (World Health Organization). Global tuberculosis report 2018. 2018 [cited 2019 18\/02\/2019]; Available from: https:\/\/www.who.int\/tb\/publications\/global_report\/en\/."},{"key":"1488_CR2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3389\/fmed.2017.00171","volume":"4","author":"A Kolloli","year":"2017","unstructured":"Kolloli A, Subbian S. Host-directed therapeutic strategies for tuberculosis. Frontiers in medicine. 2017;4:171.","journal-title":"Frontiers in medicine"},{"issue":"4","key":"1488_CR3","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1128\/MMBR.00032-13","volume":"77","author":"TR Hawn","year":"2013","unstructured":"Hawn TR, et al. Host-directed therapeutics for tuberculosis: can we harness the host? Microbiol Mol Biol Rev. 2013;77(4):608\u201327.","journal-title":"Microbiol Mol Biol Rev"},{"issue":"3","key":"1488_CR4","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/trstmh\/trw006","volume":"110","author":"J Manjelievskaia","year":"2016","unstructured":"Manjelievskaia J, et al. Drug-resistant TB: deadly, costly and in need of a vaccine. Trans R Soc Trop Med Hyg. 2016;110(3):186\u201391.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"4","key":"1488_CR5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nri3813","volume":"15","author":"RS Wallis","year":"2015","unstructured":"Wallis RS, Hafner R. Advancing host-directed therapy for tuberculosis. Nat Rev Immunol. 2015;15(4):255.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"1488_CR6","doi-asserted-by":"crossref","first-page":"1802003","DOI":"10.1183\/13993003.02003-2018","volume":"53","author":"DA Jolliffe","year":"2019","unstructured":"Jolliffe DA, et al. Adjunctive vitamin D in tuberculosis treatment: meta-analysis of individual participant data. Eur Respir J. 2019;53(3):1802003.","journal-title":"Eur Respir J"},{"issue":"4","key":"1488_CR7","first-page":"849","volume":"34","author":"A Afzal","year":"2018","unstructured":"Afzal A, et al. Efficacy of vitamin D supplementation in achieving an early sputum conversion in smear positive pulmonary tuberculosis. Pakistan J Med Sci. 2018;34(4):849.","journal-title":"Pakistan J Med Sci"},{"issue":"1","key":"1488_CR8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.it.2013.10.008","volume":"35","author":"JN Fullerton","year":"2014","unstructured":"Fullerton JN, O\u2019Brien AJ, Gilroy DW. Lipid mediators in immune dysfunction after severe inflammation. Trends Immunol. 2014;35(1):12\u201321.","journal-title":"Trends Immunol"},{"key":"1488_CR9","unstructured":"WHO (World Health Organization), Treatment of tuberculosis: guidelines. 4th edition ed, ed. WHO\/HTM\/TB\/2009.420. 2010, Geneva: World Health Organization."},{"key":"1488_CR10","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3389\/fimmu.2017.00772","volume":"8","author":"VM Kroesen","year":"2017","unstructured":"Kroesen VM, et al. Non-steroidal anti-inflammatory drugs as host-directed therapy for tuberculosis: a systematic review. Front Immunol. 2017;8:772.","journal-title":"Front Immunol"},{"key":"1488_CR11","doi-asserted-by":"crossref","unstructured":"Stek C, et al. The immune mechanisms of lung parenchymal damage in tuberculosis and the role of host-directed therapy. Front Microbiol. 2018;9.","DOI":"10.3389\/fmicb.2018.02603"},{"key":"1488_CR12","doi-asserted-by":"crossref","unstructured":"Ivanyi, J. and A. Zumla, Nonsteroidal antiinflammatory drugs for adjunctive tuberculosis treatment. J Infectious Diseases, 2013: p. jit153.","DOI":"10.1093\/infdis\/jit153"},{"issue":"3","key":"1488_CR13","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/joim.12767","volume":"284","author":"A Bekele","year":"2018","unstructured":"Bekele A, et al. Daily adjunctive therapy with vitamin D 3 and phenylbutyrate supports clinical recovery from pulmonary tuberculosis: a randomized controlled trial in Ethiopia. J Intern Med. 2018;284(3):292\u2013306.","journal-title":"J Intern Med"},{"issue":"1","key":"1488_CR14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2334-13-22","volume":"13","author":"N Salahuddin","year":"2013","unstructured":"Salahuddin N, et al. Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis\u2019. BMC Infectious Dis. 2013;13(1):22.","journal-title":"BMC Infectious Dis"},{"issue":"5","key":"1488_CR15","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1164\/rccm.201705-0936OC","volume":"196","author":"D Ganmaa","year":"2017","unstructured":"Ganmaa D, et al. High-dose vitamin D3 during tuberculosis treatment in Mongolia. A randomized controlled trial. Am J Respir Crit Care Med. 2017;196(5):628\u201337.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"1488_CR16","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1473-3099(15)70053-8","volume":"15","author":"P Daley","year":"2015","unstructured":"Daley P, et al. Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2015;15(5):528\u201334.","journal-title":"Lancet Infect Dis"},{"key":"1488_CR17","doi-asserted-by":"crossref","unstructured":"Wallis, R.S. Corticosteroid effects on sputum culture in pulmonary tuberculosis: a meta-regression analysis. In Open forum infectious diseases. 2014. Oxford University Press.","DOI":"10.1093\/ofid\/ofu020"},{"issue":"9","key":"1488_CR18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138340","volume":"10","author":"A Mily","year":"2015","unstructured":"Mily A, et al. Significant effects of oral phenylbutyrate and vitamin D3 adjunctive therapy in pulmonary tuberculosis: a randomized controlled trial. PLoS One. 2015;10(9):e0138340.","journal-title":"PLoS One"},{"issue":"38","key":"1488_CR19","doi-asserted-by":"crossref","first-page":"15449","DOI":"10.1073\/pnas.1200072109","volume":"109","author":"AK Coussens","year":"2012","unstructured":"Coussens AK, et al. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci. 2012;109(38):15449\u201354.","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"1488_CR20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070032","volume":"8","author":"AP Ralph","year":"2013","unstructured":"Ralph AP, et al. L-arginine and vitamin D adjunctive therapies in pulmonary tuberculosis: a randomised, double-blind, placebo-controlled trial. PLoS One. 2013;8(8):e70032.","journal-title":"PLoS One"},{"issue":"9761","key":"1488_CR21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(10)61889-2","volume":"377","author":"AR Martineau","year":"2011","unstructured":"Martineau AR, et al. High-dose vitamin D 3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet. 2011;377(9761):242\u201350.","journal-title":"Lancet"},{"issue":"4","key":"1488_CR22","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.4049\/jimmunol.179.4.2060","volume":"179","author":"PT Liu","year":"2007","unstructured":"Liu PT, et al. Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol. 2007;179(4):2060\u20133.","journal-title":"J Immunol"},{"issue":"3","key":"1488_CR23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ejcdt.2017.01.004","volume":"66","author":"A Farazi","year":"2017","unstructured":"Farazi A, Didgar F, Sarafraz A. The effect of vitamin D on clinical outcomes in tuberculosis. Egypt J Chest Dis Tuberculosis. 2017;66(3):419\u201323.","journal-title":"Egypt J Chest Dis Tuberculosis"},{"issue":"1","key":"1488_CR24","first-page":"47","volume":"3","author":"S Bila\u00e7ero\u011flu","year":"1999","unstructured":"Bila\u00e7ero\u011flu S, et al. Prednisolone: a beneficial and safe adjunct to antituberculosis treatment? A randomized controlled trial. Int J Tuberculosis Lung Disease. 1999;3(1):47\u201354.","journal-title":"Int J Tuberculosis Lung Disease"},{"issue":"2","key":"1488_CR25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1164\/rccm.200211-1359OC","volume":"168","author":"JL Johnson","year":"2003","unstructured":"Johnson JL, et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med. 2003;168(2):185\u201391.","journal-title":"Am J Respir Crit Care Med"},{"key":"1488_CR26","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.3389\/fimmu.2018.02069","volume":"9","author":"G Teskey","year":"2018","unstructured":"Teskey G, et al. The synergistic effects of the glutathione precursor, NAC and first-line antibiotics in the granulomatous response against Mycobacterium tuberculosis. Front Immunol. 2018;9:2069.","journal-title":"Front Immunol"},{"issue":"10","key":"1488_CR27","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1046\/j.1365-2362.2000.00736.x","volume":"30","author":"S De Rosa","year":"2000","unstructured":"De Rosa S, et al. N-acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Investig. 2000;30(10):915\u201329.","journal-title":"Eur J Clin Investig"},{"issue":"6","key":"1488_CR28","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1073\/pnas.95.6.3071","volume":"95","author":"JD Peterson","year":"1998","unstructured":"Peterson JD, et al. Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc Natl Acad Sci. 1998;95(6):3071\u20136.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"1488_CR29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0165-2478(90)90049-V","volume":"24","author":"M Denis","year":"1990","unstructured":"Denis M, Ghadirian E. Granulocyte-macrophage colony-stimulating factor restricts growth of tubercle bacilli in human macrophages. Immunol Lett. 1990;24(3):203\u20136.","journal-title":"Immunol Lett"},{"issue":"1","key":"1488_CR30","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12890-018-0677-6","volume":"18","author":"H-X Wu","year":"2018","unstructured":"Wu H-X, et al. Effects of vitamin D supplementation on the outcomes of patients with pulmonary tuberculosis: a systematic review and meta-analysis. BMC Pulmonary Med. 2018;18(1):108.","journal-title":"BMC Pulmonary Med"},{"key":"1488_CR31","doi-asserted-by":"crossref","unstructured":"Jingyan, X., et al., Impact of vitamin D supplementation on the outcome of tuberculosis treatment: a systematic review and meta-analysis of randomized controlled trials. 2014, LWW.","DOI":"10.3760\/cma.j.issn.0366-6999.20140702"},{"key":"1488_CR32","unstructured":"Riaz H, et al. Vitamin D as a supplementary agent in the treatment of pulmonary tuberculosis: a systematic review and meta-analysis of randomized controlled trials. 2013, Eur Respiratory Soc."},{"key":"1488_CR33","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/ajrccm\/147.4.1063","volume":"147","author":"C Frette","year":"1993","unstructured":"Frette C, et al. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months.[correspondence]. Am Rev Respir Dis. 1993;147:1062\u20133.","journal-title":"Am Rev Respir Dis"},{"issue":"2","key":"1488_CR34","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S1473-3099(10)70003-7","volume":"10","author":"RS Wallis","year":"2010","unstructured":"Wallis RS, et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis. 2010;10(2):68\u20139.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"1488_CR35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071116","volume":"8","author":"RS Wallis","year":"2013","unstructured":"Wallis RS, et al. Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model. PLoS One. 2013;8(8):e71116.","journal-title":"PLoS One"},{"issue":"16","key":"1488_CR36","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","volume":"313","author":"LA Stewart","year":"2015","unstructured":"Stewart LA, et al. Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement. Jama. 2015;313(16):1657\u201365.","journal-title":"Jama"},{"key":"1488_CR37","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928.","journal-title":"Bmj"},{"key":"1488_CR38","unstructured":"Higgins JP, G.S., Cochrane Handbook for Systematic Reviews of Interventions 5.3.0. Ed. the Cochrane collaboration, 2014. 2014, Oxford England: Oxford."},{"issue":"1","key":"1488_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1\u201312.","journal-title":"Control Clin Trials"},{"issue":"1","key":"1488_CR40","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/1756-0500-5-357","volume":"5","author":"FR Kayigamba","year":"2012","unstructured":"Kayigamba FR, et al. Sputum completion and conversion rates after intensive phase of tuberculosis treatment: an assessment of the Rwandan control program. BMC Research Notes. 2012;5(1):357.","journal-title":"BMC Research Notes"},{"issue":"10","key":"1488_CR41","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","volume":"61","author":"JL Peters","year":"2008","unstructured":"Peters JL, et al. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008;61(10):991\u20136.","journal-title":"J Clin Epidemiol"},{"issue":"7109","key":"1488_CR42","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, et al. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315(7109):629\u201334.","journal-title":"Bmj"},{"issue":"11","key":"1488_CR43","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"J Higgins","year":"2002","unstructured":"Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"key":"1488_CR44","first-page":"1500","volume":"1500","author":"EW Nursyam","year":"2006","unstructured":"Nursyam EW, Amin Z, Rumende CM. The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Hemoglobin. 2006;1500:1500.","journal-title":"Hemoglobin"},{"issue":"9","key":"1488_CR45","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1164\/rccm.200804-567OC","volume":"179","author":"C Wejse","year":"2009","unstructured":"Wejse C, et al. Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2009;179(9):843\u201350.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"1488_CR46","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3945\/ajcn.115.113886","volume":"102","author":"N Tukvadze","year":"2015","unstructured":"Tukvadze N, et al. High-dose vitamin D3 in adults with pulmonary tuberculosis: a double-blind randomized controlled trial. Am J Clin Nutr. 2015;102(5):1059\u201369.","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"1488_CR47","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1086\/427995","volume":"191","author":"H Mayanja-Kizza","year":"2005","unstructured":"Mayanja-Kizza H, et al. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. J Infect Dis. 2005;191(6):856\u201365.","journal-title":"J Infect Dis"},{"issue":"4","key":"1488_CR48","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/infdis\/174.4.727","volume":"174","author":"R Wallis","year":"1996","unstructured":"Wallis R, et al. Pentoxifylline therapy in human immunodeficiency virus\u2014seropositive persons with tuberculosis: a randomized, Controlled Trial. J Infectious Diseases. 1996;174(4):727\u201333.","journal-title":"J Infectious Diseases"},{"issue":"3","key":"1488_CR49","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4103\/2229-3485.210450","volume":"8","author":"SM Mahakalkar","year":"2017","unstructured":"Mahakalkar SM, et al. N-acetylcysteine as an add-on to directly observed therapy short-I therapy in fresh pulmonary tuberculosis patients: a randomized, placebo-controlled, double-blinded study. Perspectives Clin Res. 2017;8(3):132.","journal-title":"Perspectives Clin Res"},{"issue":"4","key":"1488_CR50","first-page":"245","volume":"7","author":"DB Pedral-Sampaio","year":"2003","unstructured":"Pedral-Sampaio DB, et al. Use of Rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial. Braz J Infect Dis. 2003;7(4):245\u201352.","journal-title":"Braz J Infect Dis"},{"issue":"5","key":"1488_CR51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063840","volume":"8","author":"PP Phillips","year":"2013","unstructured":"Phillips PP, Fielding K, Nunn AJ. An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. PLoS One. 2013;8(5):e63840.","journal-title":"PLoS One"},{"issue":"3","key":"1488_CR52","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1473-3099(09)70042-8","volume":"9","author":"RS Wallis","year":"2009","unstructured":"Wallis RS, et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis. 2009;9(3):162\u201372.","journal-title":"Lancet Infect Dis"},{"key":"1488_CR53","doi-asserted-by":"publisher","unstructured":"Grobler L, Nagpal S, Sudarsanam TD, Sinclair D. Nutritional supplements for people being treated for active tuberculosis. Cochrane Database Syst Rev. 2016;(6):CD006086. https:\/\/doi.org\/10.1002\/14651858.CD006086.pub4.","DOI":"10.1002\/14651858.CD006086.pub4"},{"key":"1488_CR54","doi-asserted-by":"crossref","unstructured":"Wallis, R.S. and A. Zumla. Vitamin D as adjunctive host-directed therapy in tuberculosis: a systematic review. In Open forum infectious diseases. 2016. Oxford University Press.","DOI":"10.1093\/ofid\/ofw151"},{"issue":"3","key":"1488_CR55","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1473-3099(12)70321-3","volume":"13","author":"JA Critchley","year":"2013","unstructured":"Critchley JA, et al. Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(3):223\u201337.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"1488_CR56","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1053\/j.gastro.2015.07.003","volume":"149","author":"BE Sands","year":"2015","unstructured":"Sands BE. Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology. 2015;149(5):1275\u201385 e2.","journal-title":"Gastroenterology"},{"issue":"3","key":"1488_CR57","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10067-016-3419-2","volume":"36","author":"J Sep\u00falveda-Delgado","year":"2017","unstructured":"Sep\u00falveda-Delgado J, et al. Inflammatory biomarkers, disease activity index, and self-reported disability may be predictors of chronic arthritis after chikungunya infection: brief report. Clin Rheumatol. 2017;36(3):695\u20139.","journal-title":"Clin Rheumatol"},{"key":"1488_CR58","unstructured":"Sabin, F.R., C.A. Doan, and R.S. Cunningham. Studies of the blood in experimental tuberculosis: the monocyte-lymphocyte ratio; the anemia-leucopenia phase. in Transactions of the 22nd Annual Meeting of the National Tuberculosis Association. 1926."},{"issue":"2","key":"1488_CR59","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1183\/09031936.94.07020223","volume":"7","author":"M Spatafora","year":"1994","unstructured":"Spatafora M, et al. Theophylline suppresses the release of tumour necrosis factor-alpha by blood monocytes and alveolar macrophages. Eur Respir J. 1994;7(2):223\u20138.","journal-title":"Eur Respir J"},{"issue":"2","key":"1488_CR60","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1164\/ajrccm.159.2.9804085","volume":"159","author":"LJ Marques","year":"1999","unstructured":"Marques LJ, et al. Pentoxifylline inhibits TNF-\u03b1 production from human alveolar macrophages. Am J Respir Crit Care Med. 1999;159(2):508\u201311.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1488_CR61","first-page":"53","volume":"8","author":"A Mootoo","year":"2009","unstructured":"Mootoo A, et al. TNF-\u03b1 in tuberculosis: a cytokine with a Split personality. Inflammation Allergy-Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy). 2009;8(1):53\u201362.","journal-title":"Inflammation Allergy-Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy)"},{"issue":"4","key":"1488_CR62","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/joim.12256","volume":"277","author":"A Zumla","year":"2015","unstructured":"Zumla A, et al. Inflammation and tuberculosis: host-directed therapies. J Intern Med. 2015;277(4):373\u201387.","journal-title":"J Intern Med"},{"issue":"2","key":"1488_CR63","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1183\/09031936.00007410","volume":"37","author":"W Su","year":"2011","unstructured":"Su W, et al. Role of 2-month sputum smears in predicting culture conversion in pulmonary tuberculosis. Eur Respir J. 2011;37(2):376\u201383.","journal-title":"Eur Respir J"},{"issue":"6","key":"1488_CR64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198080","volume":"13","author":"A Shibabaw","year":"2018","unstructured":"Shibabaw A, et al. Time to sputum smear and culture conversions in multidrug resistant tuberculosis at University of Gondar Hospital, Northwest Ethiopia. PloS one. 2018;13(6):e0198080.","journal-title":"PloS one"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-020-01488-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-020-01488-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-020-01488-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T10:50:33Z","timestamp":1723459833000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-020-01488-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,26]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1488"],"URL":"https:\/\/doi.org\/10.1186\/s12931-020-01488-9","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,26]]},"assertion":[{"value":"27 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Each enrolled trial was approved by the corresponding Institutional Ethical Committee for the primary trials. Thus, approval or consent of participants was not required for any of the studies included in this systematic review and meta-analysis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable<b>.<\/b>","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"223"}}